Larsen RH, Kolstad A, Fosså A, Repetto-Llamazares A, Smerud KT, Illidge T, Bruland ØS(2026) A Phase II Study of 177Lu-Lilotomab Satetraxetan, a CD37 Antibody-Radionuclide Conjugate, as Third- or Later-Line Treatment of Rituximab-Refractory Follicular B-Cell Lymphoma Patients Pharmaceuticals (Basel), 19(2) DOI 10.3390/ph19020250, PubMed 41754790
Lia K, Galleberg RB, Rostoft S, Jørgensen RRK, Smeland KB, Hjermstad MJ, Sørland K, Fagerli UM, Bø IB, Johansen J, Bhargava S, Kiserud CE, Fosså A(2026) Self-reported late effects, daily functioning, and health-related quality of life in older Hodgkin lymphoma survivors - a national population-based cross-sectional survey Leuk Lymphoma, 1-11(in press) DOI 10.1080/10428194.2026.2633180, PubMed 41761714
Övergaard N, Lia K, Collin J, Asdahl PH, Wikman P, Glimelius I, Lagerlof I, Johansson AS, Hansson L, Enblad G, Linderoth J, Goldkuhl C, Jerlström U, Fosså A, Kamper P, Molin D(2026) AVD is an effective chemotherapy backbone in first-line treatment of older patients with classical Hodgkin lymphoma Blood Adv(in press) DOI 10.1182/bloodadvances.2025018954, PubMed 41921203
